全文获取类型
收费全文 | 1791083篇 |
免费 | 137361篇 |
国内免费 | 12350篇 |
专业分类
耳鼻咽喉 | 22658篇 |
儿科学 | 56514篇 |
妇产科学 | 47248篇 |
基础医学 | 252494篇 |
口腔科学 | 50534篇 |
临床医学 | 164827篇 |
内科学 | 345938篇 |
皮肤病学 | 39744篇 |
神经病学 | 136015篇 |
特种医学 | 67906篇 |
外国民族医学 | 319篇 |
外科学 | 267444篇 |
综合类 | 59037篇 |
现状与发展 | 44篇 |
一般理论 | 536篇 |
预防医学 | 130603篇 |
眼科学 | 43220篇 |
药学 | 134772篇 |
98篇 | |
中国医学 | 11322篇 |
肿瘤学 | 109521篇 |
出版年
2021年 | 16941篇 |
2020年 | 12672篇 |
2019年 | 17427篇 |
2018年 | 23985篇 |
2017年 | 18819篇 |
2016年 | 20043篇 |
2015年 | 24229篇 |
2014年 | 32670篇 |
2013年 | 43567篇 |
2012年 | 60917篇 |
2011年 | 64504篇 |
2010年 | 38514篇 |
2009年 | 35197篇 |
2008年 | 57293篇 |
2007年 | 60505篇 |
2006年 | 60834篇 |
2005年 | 58222篇 |
2004年 | 54386篇 |
2003年 | 51431篇 |
2002年 | 49101篇 |
2001年 | 94027篇 |
2000年 | 95883篇 |
1999年 | 79311篇 |
1998年 | 20652篇 |
1997年 | 18192篇 |
1996年 | 17908篇 |
1995年 | 18071篇 |
1994年 | 16468篇 |
1993年 | 14767篇 |
1992年 | 58181篇 |
1991年 | 55947篇 |
1990年 | 53525篇 |
1989年 | 51265篇 |
1988年 | 46560篇 |
1987年 | 45296篇 |
1986年 | 42520篇 |
1985年 | 40221篇 |
1984年 | 29419篇 |
1983年 | 24929篇 |
1982年 | 13892篇 |
1979年 | 25512篇 |
1978年 | 17528篇 |
1977年 | 14849篇 |
1976年 | 13829篇 |
1975年 | 14513篇 |
1974年 | 17602篇 |
1973年 | 16907篇 |
1972年 | 15664篇 |
1971年 | 14433篇 |
1970年 | 13415篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
Espersen Caroline Modin Daniel Hoffmann Søren Hagemann Christoffer A. Hagemann Rikke A. Olsen Flemming J. Fritz-Hansen Thomas Platz Elke Møgelvang Rasmus Biering-Sørensen Tor 《The international journal of cardiovascular imaging》2022,38(1):131-140
The International Journal of Cardiovascular Imaging - Global longitudinal strain (GLS) has proven to be a powerful prognostic marker in various patient populations, but the prognostic value of... 相似文献
2.
3.
目的分析江苏省启东市1972—2016年胃癌死亡流行特征。方法收集启东市1972—2016年恶性肿瘤死亡登记数据库及历年人口资料, 计算死亡率、中国人口标化率(中标率)、世界人口标化率(世标率)、35~64岁截缩率、0~74岁累积死亡率、累积死亡风险、变化百分比、死亡率年均变化百分比。结果 1972—2016年启东市胃癌死亡例数为15 863例, 占全部恶性肿瘤死亡例数的16.04%, 胃癌死亡率为31.37/10万, 中标率为12.97/10万, 世标率为21.39/10万, 35~64岁截缩死亡率为28.86/10万, 0~74岁累积死亡率为2.54%, 胃癌死亡累积风险为2.51%。男性死亡10 114例, 男性死亡率、中标率、世标率分别为40.53/10万、17.98/10万和30.13/10万;女性死亡5 749例, 女性死亡率、中标率、世标率分别为22.45/10万、8.52/10万和13.92/10万。25岁以下各年龄组的死亡率<1/10万, 死亡率随年龄的增长而升高, 50~岁组达到并超过人群的平均死亡率水平, 80~岁组达到死亡高峰。1972—2016年间胃癌死... 相似文献
4.
5.
6.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
7.
8.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
9.
10.
S. M. White C. L. Shelton A. W. Gelb C. Lawson F. McGain J. Muret J. D. Sherman representing the World Federation of Societies of Anaesthesiologists Global Working Group on Environmental Sustainability in Anaesthesia 《Anaesthesia》2022,77(2):201-212
The Earth’s mean surface temperature is already approximately 1.1°C higher than pre-industrial levels. Exceeding a mean 1.5°C rise by 2050 will make global adaptation to the consequences of climate change less possible. To protect public health, anaesthesia providers need to reduce the contribution their practice makes to global warming. We convened a Working Group of 45 anaesthesia providers with a recognised interest in sustainability, and used a three-stage modified Delphi consensus process to agree on principles of environmentally sustainable anaesthesia that are achievable worldwide. The Working Group agreed on the following three important underlying statements: patient safety should not be compromised by sustainable anaesthetic practices; high-, middle- and low-income countries should support each other appropriately in delivering sustainable healthcare (including anaesthesia); and healthcare systems should be mandated to reduce their contribution to global warming. We set out seven fundamental principles to guide anaesthesia providers in the move to environmentally sustainable practice, including: choice of medications and equipment; minimising waste and overuse of resources; and addressing environmental sustainability in anaesthetists’ education, research, quality improvement and local healthcare leadership activities. These changes are achievable with minimal material resource and financial investment, and should undergo re-evaluation and updates as better evidence is published. This paper discusses each principle individually, and directs readers towards further important references. 相似文献